NO20092067L - 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander - Google Patents

5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander

Info

Publication number
NO20092067L
NO20092067L NO20092067A NO20092067A NO20092067L NO 20092067 L NO20092067 L NO 20092067L NO 20092067 A NO20092067 A NO 20092067A NO 20092067 A NO20092067 A NO 20092067A NO 20092067 L NO20092067 L NO 20092067L
Authority
NO
Norway
Prior art keywords
disorders
compounds
pharmaceutically acceptable
arylsulfonyl
heterocyclyl
Prior art date
Application number
NO20092067A
Other languages
English (en)
Other versions
NO341713B1 (no
Inventor
Rama Sastri Kambhampati
Venkateswarlu Jasti
Nirogi Venkata Satya Ramakrishna
Jagadishbabu Konda
Prabhakar Kothmirkar
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of NO20092067L publication Critical patent/NO20092067L/no
Publication of NO341713B1 publication Critical patent/NO341713B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Det beskrives nye 5-(heterosyklyl)alkyl-N-(arylsulfonyl)in-dolforbindelser med formel (I), samt deres derivater, stereoisomerer, farmasøytisk akseptable salter og farmasøytisk akseptable preparater som inneholder forbindelsene. Det beskrives videre en fremgangsmåte for fremstilling av nevnte nye forbindelser, deres derivater, stereoisomerer, deres farmasøytisk akseptable salter og farmasøytisk akseptable preparater inneholdende disse. Forbindelsene er nyttige ved behandling av forskjellige forstyrrelser som er relatert til 5-HT6-reseptorfunksjoner. Spesielt er forbindelsene ifølge oppfinnelsen også nyttige ved behandling av forskjellige CNS-forstyrrelser, hematologiske forstyrrelser, spiseforstyrrelser, sykdommer assosiert med smerte, respiratoriske sykdommer, genitourologiske forstyrrelser, kardiovaskulære sykdommer og cancer.
NO20092067A 2007-01-08 2009-05-27 5-(Heterosyklyl)alkyl-n-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander NO341713B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN45CH2007 2007-01-08
PCT/IN2007/000312 WO2008084492A1 (en) 2007-01-08 2007-07-26 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
NO20092067L true NO20092067L (no) 2009-09-04
NO341713B1 NO341713B1 (no) 2018-01-08

Family

ID=39495814

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092067A NO341713B1 (no) 2007-01-08 2009-05-27 5-(Heterosyklyl)alkyl-n-(arylsulfonyl)indolforbindelser og deres anvendelse som 5-HT6-ligander

Country Status (22)

Country Link
US (1) US8470830B2 (no)
EP (1) EP2114878B1 (no)
JP (1) JP2010515674A (no)
KR (1) KR101103023B1 (no)
CN (1) CN101553467B (no)
AT (1) ATE491685T1 (no)
AU (1) AU2007343063B2 (no)
BR (1) BRPI0718737A2 (no)
CA (1) CA2670717C (no)
CY (1) CY1111105T1 (no)
DE (1) DE602007011323D1 (no)
DK (1) DK2114878T3 (no)
EA (1) EA017007B1 (no)
ES (1) ES2357584T3 (no)
IL (1) IL198821A (no)
MX (1) MX2009006077A (no)
NO (1) NO341713B1 (no)
NZ (1) NZ577769A (no)
PL (1) PL2114878T3 (no)
PT (1) PT2114878E (no)
WO (1) WO2008084492A1 (no)
ZA (1) ZA200903600B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
CN103304547A (zh) * 2012-03-13 2013-09-18 中国药科大学 一种抗抑郁药维拉唑酮的制备方法
WO2015074123A1 (en) * 2013-11-25 2015-05-28 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) * 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof
US20170152226A1 (en) * 2014-07-16 2017-06-01 Novogen Ltd. Functionalised and substituted indoles as anti-cancer agents
TW202216676A (zh) 2020-07-06 2022-05-01 美商塔朵根公司 用於心理疾病或心理強化的有益苯并噻吩組合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9026389D0 (en) * 1990-12-05 1991-01-23 Merck Sharp & Dohme Therapeutic agents
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (en) 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
ATE375990T1 (de) 1999-04-21 2007-11-15 Nps Allelix Corp Piperidin-indol derivate mit 5-ht6 affinität
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
JP4184077B2 (ja) 2000-11-02 2008-11-19 ワイス ５−ヒドロキシトリプトアミン−６リガンドとしての１−アリールまたは１−アルキルスルホニル−ヘテロシクリルベンザゾール
ATE340795T1 (de) 2001-01-30 2006-10-15 Lilly Co Eli Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
CN100439370C (zh) 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
BR0210929A (pt) 2001-06-07 2004-06-08 Hoffmann La Roche Derivados de indol com afinidade para o receptor 5-ht6
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
WO2003065046A2 (en) 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
AU2003244452A1 (en) 2002-02-05 2003-09-02 Glaxo Group Limited Method of promoting neuronal growth
RU2309154C9 (ru) 2002-03-27 2016-09-27 Глэксо Груп Лимитед 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты)
JP4559230B2 (ja) 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物
MXPA05005700A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxiindoles.
AU2003292508A1 (en) 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
EA009367B1 (ru) 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
WO2004108671A1 (en) * 2003-06-06 2004-12-16 Suven Life Sciences Limited Substituted indoles with serotonin receptor affinity, process for their preparation and pharmaceutical compositions containing them
ES2222828B1 (es) 2003-07-30 2006-04-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos.
BRPI0520579B8 (pt) 2005-08-12 2021-05-25 Suven Life Sciences Ltd composto, processo para a preparação de um composto e composição farmacêutica
CA2655694C (en) * 2006-07-03 2014-12-16 Biovitrum Ab (Publ) 1,4-substituted indoles useful for modulation of the 5-ht6 receptor

Also Published As

Publication number Publication date
ES2357584T3 (es) 2011-04-27
EP2114878A1 (en) 2009-11-11
IL198821A0 (en) 2010-02-17
BRPI0718737A2 (pt) 2014-03-25
CN101553467A (zh) 2009-10-07
HK1132273A1 (en) 2010-02-19
KR20090080544A (ko) 2009-07-24
MX2009006077A (es) 2009-06-17
DE602007011323D1 (de) 2011-01-27
PT2114878E (pt) 2011-03-10
PL2114878T3 (pl) 2011-05-31
CA2670717A1 (en) 2008-07-17
IL198821A (en) 2014-11-30
US8470830B2 (en) 2013-06-25
CY1111105T1 (el) 2015-06-11
AU2007343063A8 (en) 2009-07-23
CA2670717C (en) 2012-01-10
WO2008084492A1 (en) 2008-07-17
ATE491685T1 (de) 2011-01-15
KR101103023B1 (ko) 2012-01-05
ZA200903600B (en) 2010-07-28
AU2007343063A1 (en) 2008-07-17
NZ577769A (en) 2011-01-28
US20100041673A1 (en) 2010-02-18
AU2007343063B2 (en) 2011-02-17
EA017007B1 (ru) 2012-09-28
NO341713B1 (no) 2018-01-08
JP2010515674A (ja) 2010-05-13
CN101553467B (zh) 2011-12-07
EA200970675A1 (ru) 2009-12-30
EP2114878B1 (en) 2010-12-15
DK2114878T3 (da) 2011-03-14

Similar Documents

Publication Publication Date Title
MY192354A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
MY167135A (en) Fused heterocyclic derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MY156822A (en) Indole derivatives as s1p1 receptor agonists
NO20092067L (no) 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2007002393A (es) Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6).
CY1111836T1 (el) Ενωσεις aminoalkoxy aryl sulfonamide και η χρηση τους σαν συνδετων (ligands) 5-ητ6
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2009006757A (es) Compuestos de 4-(heterociclil)alquil-n-(arilsulfonil) indol y su uso como ligandos de la 5-hidroxitriptamina6.
CY1112181T1 (el) Αμινο αρυλοσουλφοναμιδικες ενωσεις και η χρηση τους ως 5-ητ6 συνδετες
BR112014006675A2 (pt) derivados de metanossulfonamida substituídos como ligantes de receptor vaniloide
TW200640904A (en) Quinazoline derivatives
WO2014147636A8 (en) 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
WO2010012806A3 (en) Substituted indole sulfonamide compounds, their preparation and use as medicaments

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees